Prostate cancer
Conditions
Interventions
therapy group:Docetaxel plus platinum chemotherapy
Sponsors
Huadong Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
Male
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Male, >=18 years old; 2. Pathologically confirmed prostate adenocarcinoma (prostate cancer, Pca); 3. The disease progresses after castration treatment, and the blood testosterone reaches the castration level; 4. The new generation of endocrine therapy drugs (abiraterone or enzalutamide, etc.) are resistant or not suitable for the new generation of endocrine therapy; 5. No chemotherapy (except estradiol phosphate mustard); 6. The DNA damage repair gene abnormality has been confirmed by the second-generation DNA sequencing technology; 7. Physical condition can tolerate chemotherapy; 8. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Received Pca chemotherapy in the past (except estradiol, except those who have completed adjuvant/neoadjuvant chemotherapy for more than 3 years, and those who have completed chemotherapy in the metastatic hormone-sensitive stage for more than 1 year); 2. There is a history of brain metastases, uncontrolled spinal cord compression or cancerous meningitis, or signs of new brain or leptomeningeal disease; 3. Any of the following conditions within 6 months before entering the study: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, NYHA class III or IV congestive heart failure, stroke or transient brain ischemic attack; 4. Previous use of PARP inhibitors; 5. History of docetaxel or platinum allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prostate specific antigen;bone scan; | — |
Secondary
| Measure | Time frame |
|---|---|
| gene test; | — |
Countries
China
Contacts
Public ContactSheng Lu
Huadong Hospital Affiliated to Fudan University
Outcome results
None listed